Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGOBSERVATIONAL

Monocentric Observational Study on the Diagnostic and Prognostic Role of 18F-PSMA PET (PET/CT and PET/MR) in Prostate Cancer

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The general objective of this retrospective and prospective study is to evaluate the diagnostic and prognostic role of a quantitative analysis of PET images with 18F-PSMA in all stages of the disease in patients with prostate cancer. To this end, both imaging parameters commonly used in clinical practice and the contribution of radiomic features will be investigated. The latter are quantitative features extracted from biomedical images, and are believed to be able to provide information, otherwise impossible to investigate, useful for the characterization of various pathologies. This methodology is very promising, but also recent and therefore little studied and standardized. Our objective is also to investigate how to optimize it from a purely methodological point of view.

Who May Be Eligible (Plain English)

Who May Qualify: - adult male patients; - patients with histopathological diagnosis of prostate cancer undergoing staging or restaging; - patients with clinical indication for PET examination with 18 F-PSMA; Who Should NOT Join This Trial: - medical conditions that do not allow the acquisition of PET images; - allergic reactions to iodinated contrast medium or creatinine levels \>2mg/dL. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * adult male patients; * patients with histopathological diagnosis of prostate cancer undergoing staging or restaging; * patients with clinical indication for PET examination with 18 F-PSMA; Exclusion Criteria: * medical conditions that do not allow the acquisition of PET images; * allergic reactions to iodinated contrast medium or creatinine levels \>2mg/dL.

Treatments Being Tested

DIAGNOSTIC_TEST

PET 18F-PSMA

Subjects will be subjected to a PET examination according to international guidelines and where requested by the specialist. In particular, patients will be administered the radiopharmaceutical 18 F PSMA. Approximately two hours after administration, the patient is positioned on the PET/CT equipment table and image acquisition begins.

Locations (1)

IRC
Milan, Italy